Skip to main content
Evidence Snapshot

Dual specificity protein kinase CLK2

CHEMBL4225 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4225
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dual specificity protein kinase CLK2 as ChEMBL target CHEMBL4225, mapped to UniProt P49760. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dual specificity protein kinase CLK2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4225
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P49760
Dual specificity protein kinase CLK2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Dual specificity protein kinase CLK2 matters

As of 2026-09-13

Dual specificity protein kinase CLK2 is reviewed as Dual specificity protein kinase CLK2 (UniProt P49760); Dual specificity protein kinase CLK2 shows late clinical disease relevance led by osteoarthritis, knee. 2 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 15 approved drugs, 3365 compounds, and 445 assays, with lead potency reaching pChEMBL 10.0.

Disease context
osteoarthritis, knee

Dual specificity protein kinase CLK2 shows late clinical disease relevance led by osteoarthritis, knee. 2 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include LORECIVIVINT.

Start review with osteoarthritis, knee because it currently carries late clinical support. Linked drugs include LORECIVIVINT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 15 approved drugs, 3365 compounds, and 445 assays for this target. The dominant activity type is KI. CHEMBL4797564 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL4797564 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
15 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Dual specificity protein kinase CLK2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P49760, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why osteoarthritis, knee is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3365
Total Compounds
445
Total Assays
15
Approved Drugs
IC50: 700.0, KI: 915.0, EC50: 643.0, KD: 365.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4797564
 10.0 Kd —
No preferred name
CHEMBL4797564
 10.0 IC50 —
No preferred name
CHEMBL4546504
 9.6 IC50 —
No preferred name
CHEMBL3544966
 9.4 Kd —
No preferred name
CHEMBL379218
 9.3 Kd —

Approved Drugs

Structure Compound First Approval
ENTRECTINIB
CHEMBL1983268
 2019
ABEMACICLIB
CHEMBL3301610
 2017
BRIGATINIB
CHEMBL3545311
 2017
MIDOSTAURIN
CHEMBL608533
 2017
PALBOCICLIB
CHEMBL189963
 2015
NINTEDANIB
CHEMBL502835
 2014
RUXOLITINIB
CHEMBL1789941
 2011
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4225